465 related articles for article (PubMed ID: 24993163)
21. The BRAF p.V600E mutation is a common event in ameloblastomas but is absent in odontogenic keratocysts.
Zhang R; Yang Q; Qu J; Hong Y; Liu P; Li T
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Mar; 129(3):229-235. PubMed ID: 31987674
[TBL] [Abstract][Full Text] [Related]
22. Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas.
Sviatoha V; Tani E; Ghaderi M; Kleina R; Skoog L
Anticancer Res; 2010 Sep; 30(9):3267-72. PubMed ID: 20944096
[TBL] [Abstract][Full Text] [Related]
23. Activating mutations in the RAS/mitogen-activated protein kinase signaling pathway in sporadic trichoblastoma and syringocystadenoma papilliferum.
Shen AS; Peterhof E; Kind P; Rütten A; Zelger B; Landthaler M; Berneburg M; Hafner C; Groesser L
Hum Pathol; 2015 Feb; 46(2):272-6. PubMed ID: 25532942
[TBL] [Abstract][Full Text] [Related]
24. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
25. The importance of BRAF-V600E mutation to ameloblastoma metabolism.
Duarte-Andrade FF; Silva AMB; Vitório JG; Canuto GAB; Costa SFS; Diniz MG; Fernandes AP; de Toledo JS; André LC; Gomes CC; Gomez RS; Fonseca FP
J Oral Pathol Med; 2019 Apr; 48(4):307-314. PubMed ID: 30739334
[TBL] [Abstract][Full Text] [Related]
26. Genetic study of the BRAF gene reveals new variants and high frequency of the V600E mutation among Iranian ameloblastoma patients.
Soltani M; Tabatabaiefar MA; Mohsenifar Z; Pourreza MR; Moridnia A; Shariati L; Razavi SM
J Oral Pathol Med; 2018 Jan; 47(1):86-90. PubMed ID: 28650588
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of allele-specific PCR and immunohistochemistry for the detection of BRAF V600E mutations in hairy cell leukemia.
Brown NA; Betz BL; Weigelin HC; Elenitoba-Johnson KS; Lim MS; Bailey NG
Am J Clin Pathol; 2015 Jan; 143(1):89-99. PubMed ID: 25511147
[TBL] [Abstract][Full Text] [Related]
28. BRAF-V600E expression correlates with ameloblastoma aggressiveness.
Fregnani ER; Perez DE; Paes de Almeida O; Fonseca FP; Soares FA; Castro-Junior G; Alves FA
Histopathology; 2017 Feb; 70(3):473-484. PubMed ID: 27681305
[TBL] [Abstract][Full Text] [Related]
29. The molecular basis of odontogenic cysts and tumours.
Gomes IP; Bastos VC; Guimarães LM; Gomes CC
J Oral Pathol Med; 2023 Apr; 52(4):351-356. PubMed ID: 36629457
[TBL] [Abstract][Full Text] [Related]
30. [BRAF V600E expression in ameloblastomas, ameloblastic carcinomas and cysts].
Pei J; Zhang L; Jia YX; Chen WH
Shanghai Kou Qiang Yi Xue; 2023 Dec; 32(6):630-634. PubMed ID: 38494972
[TBL] [Abstract][Full Text] [Related]
31. Detection and evaluation of the presence of the BRAF V600E mutation in ameloblastomas in an Indian population.
Goes CF; Spadigam A; Dhupar A; Carvalho KM; Cota J; Syed S
Indian J Pathol Microbiol; 2023; 66(2):246-251. PubMed ID: 37077063
[TBL] [Abstract][Full Text] [Related]
32. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.
Capper D; Preusser M; Habel A; Sahm F; Ackermann U; Schindler G; Pusch S; Mechtersheimer G; Zentgraf H; von Deimling A
Acta Neuropathol; 2011 Jul; 122(1):11-9. PubMed ID: 21638088
[TBL] [Abstract][Full Text] [Related]
33. Frequency of BRAF V600E mutation in a group of Thai patients with ameloblastomas.
Lapthanasupkul P; Laosuk T; Ruangvejvorachai P; Aittiwarapoj A; Kitkumthorn N
Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Nov; 132(5):e180-e185. PubMed ID: 32665205
[TBL] [Abstract][Full Text] [Related]
34. Advancements in MAPK signaling pathways and MAPK-targeted therapies for ameloblastoma: A review.
You Z; Liu SP; Du J; Wu YH; Zhang SZ
J Oral Pathol Med; 2019 Mar; 48(3):201-205. PubMed ID: 30489659
[TBL] [Abstract][Full Text] [Related]
35. Association of MDM2 Overexpression in Ameloblastomas with
Tosios KI; Kalogirou EM; Koutlas IG
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396916
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas.
do Canto AM; da Silva Marcelino BMR; Schussel JL; Wastner BF; Sassi LM; Corrêa L; de Freitas RR; Hasséus B; Kjeller G; Junior CAL; Braz-Silva PH
Clin Oral Investig; 2019 Feb; 23(2):779-784. PubMed ID: 29855709
[TBL] [Abstract][Full Text] [Related]
37. BRAF V600E mutation-specific immunohistochemical analysis in ameloblastomas: a 44-patient cohort study from a single institution.
Owosho AA; Ladeji AM; Adebiyi KE; Olajide MA; Okoye ISI; Kehinde T; Nwizu NN; Summersgill KF
Eur Arch Otorhinolaryngol; 2021 Aug; 278(8):3065-3071. PubMed ID: 33231757
[TBL] [Abstract][Full Text] [Related]
38. Mutations in PIK3CA are infrequent in neuroblastoma.
Dam V; Morgan BT; Mazanek P; Hogarty MD
BMC Cancer; 2006 Jul; 6():177. PubMed ID: 16822308
[TBL] [Abstract][Full Text] [Related]
39. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
40. Ameloblastoma with mucous cells: A clinicopathological, BRAF mutation, and MAML2 rearrangement study.
Xia RH; Zhang CY; Sun JJ; Tian Z; Hu YH; Gu T; Wang LZ; Li J
Oral Dis; 2020 May; 26(4):805-814. PubMed ID: 31954088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
